Drug Utilization Review

Federal regulations at 42 C.F.R. � 456.703 - 456.725 require that Medicaid pharmacy programs establish and maintain a Drug Utilization Review (DUR) program that helps to ensure appropriate drug utilization by conducting prospective and retrospective drug utilization review, and maintaining an educational program. These regulations also require that state Medicaid pharmacy programs establish and maintain a DUR Board. More information about the DUR Board, including membership lists, meeting schedules, and meeting minutes can be found on the DUR Board Web page.

Educational Materials

As part of the drug utilization review process, including those reviews performed under the Four Prescription Policy, the department identifies common clinical issues for which updated educational information might be useful. These educational materials, which have been prepared by the department and the University of Illinois at Chicago College of Pharmacy, and approved by the Drug Utilization Review Board, are intended to be a resource for prescribers in an effort to improve the quality of care for our beneficiaries.

Naloxone

� U.S. Surgeon General�s Advisory on Naloxone and Opioid Overdose

� Illinois Department of Public Health: Naloxone standing order and patient education materials

Pain Management with Opioids

CDC

� CDC Factsheet: Calculating total daily dose of opioids for safer dosage (pdf)

� CDC Opioid prescribing guideline mobile app (pdf) App Store Google Play

� CDC Guideline for prescribing opioids for chronic pain - United States, 2016

� CDC Guidelines At-A-Glance

FDA

� FDA's Opioid Analgesic REMS Patient Counseling guide (pdf) Spanish version (pdf)

� FDA's Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain (pdf)

� FDA: The Opioid Epidemic: What veterinarians need to know

� FDA limits use of opioid containing cough and cold products in children

� FDA's new black box warning about concomitant use of opioids with benzodiazepines FDA's new black box warning about concomitant use of opioids with benzodiazepines� FDA's new black box warning about concomitant use of opioids with benzodiazepines

HFS

� Use of medications containing codeine and tramadol in children (pdf)

� U.S. Department of Health and Human Services: Opioids: the prescription drug and heroin overdose epidemic

� Fentanyl products non-preferred in Illinois Medicaid (pdf)

� Methadone for pain non-preferred in Illinois Medicaid (pdf)

� Opioid Pain Management: Provider Continuing Education Resources (pdf) (html)

Medical Professional Organizations

� Opioids for chronic noncancer pain. A position paper of the American Academy of Neurology

� Opioid prescribing: A systematic review and critical appraisal of guidelines for chronic pain (pdf)

� Safe Narcotic Prescribing (pdf)

Illinois Prescription Monitoring Program

Effective January 1, 2018, the Illinois Controlled Substances Act was amended. All Illinois prescribers with an Illinois controlled substances license must register with the Prescription Monitoring Program and attempt to access the program to assess patient access to controlled substances. Please see the Illinois Prescription Monitoring program webpage for more information.

Asthma

� Asthma Therapy: Quick Reference Guide (pdf)

� Montelukast's Role in the Treatment of Asthma (pdf)

Benzodiazepine Therapy

VA: Re-evaluating the use of benzodiazepines. A focus on high-risk populations https://www.pbm.va.gov/PBM/AcademicDetailingService/Documents/Academic_Detailing_Educational_Material_Catalog/22_Benzodiazepine_Provider_AD_Educational_Guide_IB_10_928.pdf
VA: Patient/Provider Discussion Guide: Benzodiazepine risks, discontinuation, and taper. https://www.pbm.va.gov/PBM/AcademicDetailingService/Documents/Academic_Detailing_Educational_Material_Catalog/24_Benzodiazepines_Provider_AD_Risk_Discussion_Guide_IB10_953.pdf
Judicious prescribing of benzodiazepines from NY City Dept Health and Mental Hygiene http://www1.nyc.gov/assets/doh/downloads/pdf/chi/chi-35-2.pdf

Safe prescribing of benzodiazepines for anxiety and insomnia from Pennsylvania. http://www.overdosefreepa.pitt.edu/wp-content/uploads/2016/10/Benzo-for-anxiety-and-insomnia-FINAL-002.pdf

Cardiovascular Disease

Diabetes

Migraine Prophylaxis (pdf) (html)

Resources for Managing Vitamin D Therapy (pdf) (html)

Safe use of acetaminophen-containing combination products (pdf)

Claims Processing Drug Utilization Control Edits

HFS routinely reviews drug claims to identify problematic utilization patterns. As a result, HFS implements edits in the claims processing system to prevent inappropriate utilization such as therapeutic duplication, excessive duration of therapy, off-label use of drugs without clinical support, and filling of unnecessary drugs/products. Once a claims processing edit is in place, on a case-by-case basis and where appropriate, the Department can override an edit through the drug prior approval system.

Site Navigation